Anadis to commercialise BioGard
Thursday, 04 September, 2008
Anadis [ASX: ANX] is to begin commercialisation of BioGard, a treatment designed to maintain gastrointestinal and immune system health.
The treatment, aimed at people undergoing antiretroviral therapy for HIV/AIDS, will be marketed as medical food.
BioGard's active ingredient is a formulation of antigen-targeted Bovine Clostrum Powder (BCP). The cows from which the powder is sourced will be vaccinated with a mixture of lipopolysaccarides implicated as key drivers of AIDS pathogenesis.
It will at first be made available in tablet form, sold over-the-counter but intended for use under medical supervision.
The product's ingredients and manufacturing process has been approved by the TGA.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
